Trigonella, Foeniculum, Chichorium in prevention of cancer-induced cachexia/anorexia

Evaluation of the herbal combination of Cichorium inyubus, Trigonella foenum-graecum and Foeniculum vulgare in the prevention of cancer-induced cachexia/anorexia in solid tumours’ patients: a randomized, double-blinded, placebo-controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180722040556N2

Enrollment

Registered

2019-10-06

Start date

2018-07-26

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer-induced cachexia. Malignant neoplasm without specification of site

Interventions

Intervention 1: Intervention group: Herbal combination including Trigonella, Foeniculum, Chichorin provided in Dineh company named Chicoridine, one tablet three times a day for eight weeks. Interventi

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All adult patients (18 years and older) with advanced solid malignant tumour (Stage 3-4) who encountered cancer-induced anorexia or weight loss (equal or greater than 5% of the previous weight before cancer diagnosis or within the last two months). Cancer patients with serum creatinine < 2 mg /dl and serum total bilirubin < 2 mg /dl. Patients should not have any sign of dysphagia or gastrointestinal obstruction. The patients' life expectancy should be at least 3 months. Patients who are taking high doses of megestrol due to cachexia and anorexia simultaneously.

Exclusion criteria

Exclusion criteria: Patients who have undergone major surgery during the last 4 weeks. Patients with a history of thrombophlebitis diseases. Patients who have been taking systemic corticosteroid within the last 4 weeks or concurrently. Patients who have cognitive impairment, psychiatric disorder or brain metastasis leading to cognitive impairment. Patients who have diabetes, uncontrolled blood pressure or advanced heart failure (NYHA 4) Patients who are alcoholic. Patients who are pregnant or breast-feeding. Patients with a known hypersensitivity reaction to one of the plants in study herbal combination.

Design outcomes

Primary

Measure	Time frame
Cachexia/anorexia. Timepoint: Baseline and 8 weeks later. Method of measurement: Edmonton criteria.	—

Secondary

Measure	Time frame
Quality of life. Timepoint: Baseline and eight weeks later. Method of measurement: Iranian Version of the EORTC QLQ.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Moghaddas

Esfahan University of Medical Sciences

azadeh_moghaddas@yahoo.com+98 31 3792 7074

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026